AEON Biopharma (AEON) Share-based Compensation (2022 - 2026)
AEON Biopharma (AEON) posted Share-based Compensation of $1.6 million for Q4 2025, down 53.18% sequentially from $3.4 million in Q3 2025, and up 17.93% YoY from $1.3 million in Q4 2024.
AEON Biopharma (AEON) Share-based Compensation (2022 - 2026) Analysis & Trends
AEON Biopharma has reported Share-based Compensation for 4 years, with the latest figure at $1.6 million in Q4 2025.
- Quarterly Share-based Compensation rose 17.93% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.3 million (changed 0.0% YoY) and the FY2025 annual result came in at $5.3 million, down 14.93% from the prior year.
- Share-based Compensation slipped to $1.6 million in Q4 2025 per AEON's latest filing, from $3.4 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.4 million in Q3 2025 and troughed at $900000.0 in Q4 2023.
- A 4-year average of $1.6 million and a median of $1.6 million in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation slumped 46.81% in 2023, then surged 112.5% in 2025.
- Over 4 years, Share-based Compensation stood at $1.7 million in 2022, then plunged by 46.81% to $900000.0 in 2023, then jumped by 50.0% to $1.3 million in 2024, then increased by 17.93% to $1.6 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.6 million, $3.4 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | - |
| 10 | AEON Biopharma | 9.71 Mn | 6.28 Mn | - | 1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.90 Mn |
| Jun 30, 2026 | 1.90 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |